OTCQB: PHRRF | CSE: PHRM
PharmaTher (OTCQB: PHRRF) (CSE: PHRM)
  • HOME
    • TEAM
  • PORTFOLIO
    • PERSONALIZ3D™
    • KetaMist®
    • Psychedelics
    • Investments
  • INVESTORS
  • NEWS
  • HOME
    • TEAM
  • PORTFOLIO
    • PERSONALIZ3D™
    • KetaMist®
    • Psychedelics
    • Investments
  • INVESTORS
  • NEWS

Press Releases

8/14/2025

PharmaTher Founder and CEO Issues Letter to Shareholders following the FDA Approval of Ketamine

 

Read More

8/11/2025

PharmaTher Announces FDA Approval of Ketamine

 

Read More

7/2/2025

PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine

 

Read More

6/24/2025

PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market

 

Read More

6/18/2025

PharmaTher Applauds FDA's New Commissioner’s National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications

 

Read More

5/16/2025

PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025

 

Read More

5/14/2025

PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization

 

Read More

3/11/2025

PharmaTher Receives US FDA Approval Goal Date for Ketamine

 

Read More

3/3/2025

PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine

 

Read More

2/12/2025

PharmaTher Provides Update on FDA New Drug Application for Ketamine

 

Read More

1/6/2025

PharmaTher CEO Issues Letter to Shareholders

 

Read More

11/26/2024

PharmaTher Announces Update on FDA New Drug Application for Ketamine

 

Read More

11/19/2024

PharmaTher Announces Update on FDA New Drug Application for Ketamine

 

Read More

11/13/2024

PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application

 

Read More

10/23/2024

PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application

 

Read More

9/4/2024

PharmaTher Announces Update on FDA New Drug Application for Ketamine

 

Read More

8/21/2024

PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins

 

Read More

8/19/2024

PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)

 

Read More

5/15/2024

PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine

 

Read More

5/10/2024

PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine

 

Read More

5/1/2024

PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine

 

Read More

4/18/2024

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

 

Read More

4/16/2024

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

 

Read More

2/21/2024

PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of  Patented Reformulated Cepharanthine for Phase 1 Study in Australia

 

Read More

2/12/2024

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

 

Read More
Previous
Forward

    Archives

    July 2026
    May 2026
    April 2026
    March 2026
    February 2026
    January 2026
    December 2025
    November 2025
    October 2025
    August 2025
    July 2025
    June 2025
    May 2025
    March 2025
    February 2025
    January 2025
    November 2024
    October 2024
    September 2024
    August 2024
    May 2024
    April 2024
    February 2024
    January 2024
    September 2023
    July 2023
    June 2023
    May 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020

Psychedelic Pharmaceuticals
PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario, M5C 1P1
​Canada
​Tel: 1-888-846-3171
Email Us
© COPYRIGHT 2026.  PharmaTher Holdings Ltd.   ALL RIGHTS RESERVED.
"The product candidates described on this website are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established."